Objective: To evaluate the safety and efficacy of bimatoprost 0.03% (Lumigan) monotherapy in patients with glaucoma or ocular hypertension previously treated with timolol 0.5% gel-forming solution (Timoptic-XE) and latanoprost 0.005% (Xalatan) dual therapy. Methods: An open-label, multicenter e-valuation of 83 patients. Patients were assigned to dual therapy with latanoprost qPM and timolol gel-forming solu- Objective: To evaluate the safety and efficacy of bimatoprost 0.03% (Lumigan) monotherapy in patients with glaucoma or ocular hypertension previously treated with timolol 0.5% gel-forming solution (Timoptic-XE) and latanoprost 0.005% (Xalatan) dual therapy. An open-label, multicenter e-valuation of 83 patients. Patients were assigned to dual therapy with latanoprost qPM and timolol gel-forming solu-